CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Genetic Technologies Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Genetic Technologies Ltd
Suite 7, Level 1, 321 Chapel Street
Phone: +61 394151135p:+61 394151135 MELBOURNE, VIC  3181  Australia Ticker: GTGGTG
Placed into Administration on 11/20/2024
On 11/20/2024, Genetic Technologies Limited was placed under Voluntary Administration with Ross Blakeley and Paul Harlond of FTI Consulting appointed as Joint and Several Voluntary Administrators pursuant to section 436A of the Corporations Act 2001.
Business Summary
Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20246/30/2024YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8071 Medical laboratories
8731 Commercial physical and biological research
2835 In vitro and in vivo diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board Peter I.Rubinstein 5/18/2020 1/31/2018
Chief Executive Officer SimonMorriss 2/1/2021 2/1/2021
Chief Financial Officer, Company Secretary MarkZiirsen 60 7/16/2024 7/16/2024
5 additional Officers and Directors records available in full report.

Business Names
Business Name
AffinityDNA
Co Ltd
EasyDNA
15 additional Business Names available in full report.

General Information
Number of Employees: 58 (As of 6/30/2024)
Outstanding Shares: 245,362,077 (As of 8/6/2024)
Shareholders: 4,528
Stock Exchange: ASX
Federal Tax Id: 000000000
Fax Number: +61 384127040


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, November 22, 2024